That AZ post should be enlightening to folks. AZD9291 is the triple threat we were promised with '113. EGFR and T790. A weekend of posts here and a $31.50 pretty much wasted.
We lost 18 months because of lessons unlearned, should have been learned. So Ponatinib was snafu'd, '113 facing very strong competition. The same folks will be making decisions on molecule next. We have great science, horrible supporting management decisions.
Maybe folks think management is just fine, or better. If so, then I can understand your happiness because your inaction means protection, bliss and perpetuity for them.
We need smarter folks in there for molecule next. Or at least to accept a buyout so we don't lose even more value.
Sometimes I am in disbelief of the low hurdle folks here maintain for management when mgmt. have proven they have difficulty meeting even that. Think about that.
